Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
September 27, 2023
-
BUSINESS Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
-
REGULATORY Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
-
REGULATORY Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
-
ACADEMIA Academic Society Condemns Off-Label Use of GLP-1 Diabetes Drugs as Shipment Curbs Persist
September 25, 2023
-
BUSINESS LTL Pharma Sees “G1” LLP Price Cuts as Business Opportunity: President
September 22, 2023
-
REGULATORY Sitagliptin Increases Cancer Risk in 1 in 115,000 People with Current Global Impurity Limit: Makers
September 22, 2023
-
BUSINESS Lecanemab to Serve as Gamechanger in Science, Treatments Set to Start by Year-End: Biogen Japan Chief
September 21, 2023
-
REGULATORY Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
-
REGULATORY MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
-
REGULATORY Japan to End Use of Original COVID Vaccine, Previous Omicron Jabs
September 20, 2023
-
ORGANIZATION JPMA Embarking on Creation of One-Stop Platform for Rare Disease Trial Info
September 19, 2023
-
REGULATORY Japan to Require Out-of-Pocket Cost for COVID Drugs from October
September 19, 2023
-
REGULATORY New Health Minister Vows to Put Public Needs First in 2024 Drug Pricing Reform
September 15, 2023
-
REGULATORY Japan to Basically Drop Japanese PI Requirement before Global Clinical Trials
September 14, 2023
-
REGULATORY Chuikyo Mixed on Expanding Range of CEA Price Adjustments for Pricey Meds
September 14, 2023
-
REGULATORY Keizo Takemi Tapped as New Health Minister in Cabinet Reshuffle
September 14, 2023
-
REGULATORY Japan’s Envisaged IP Tax Relief Likely to Cover Drug Sales, METI Eyes FY2024 Rollout
September 13, 2023
-
REGULATORY Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
September 12, 2023
-
REGULATORY New MHLW Drug Review Chief Vows to Make Japan Attractive Place for Clinical Trials, Watching Debate on Japanese PI
September 12, 2023
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…